What Crossbow Therapeutics does

Crossbow Therapeutics is a clinical-stage biotechnology company developing T-cell engager (TCE) immunotherapies that target intracellular cancer proteins presented as peptide-HLA complexes—a class of antigens inaccessible to conventional antibody drugs and existing TCEs that rely on cell-surface proteins. The company's proprietary T-Bolt™ platform combines TCR-mimetic antibody discovery with bispecific T-cell engager architecture, enabling precise targeting of tumor-specific pHLA complexes while maintaining antibody manufacturability.

The pipeline is anchored by CBX-250, a first-in-class bispecific TCE targeting the cathepsin G (CTSG) CG1 pHLA complex for relapsed/refractory AML, HR-MDS, and CMML, which entered a Phase 1 trial (CROSSCHECK-001, NCT06994676) in September 2025. The second program, CBX-663, is a TERT-targeting TCE with dual TERT-binding domains for solid tumor and hematologic malignancies, with an IND filing targeted for Q3 2026. Two earlier-stage programs (CBX-589, CBX-880) extend the pipeline. A strategic collaboration with MD Anderson Cancer Center provides target validation and binder discovery capabilities.

The company is pre-commercial and headquartered in Cambridge, Massachusetts, with revenue expected to derive from future pharmaceutical licensing, co-development deals, milestones, and royalties. It has raised over $157 million across a Series A ($80M, July 2023, led by MPM BioImpact and Pfizer Ventures) and a Series B ($77M, March 2026, co-led by Taiho Ventures and Arkin Bio Capital), with Eli Lilly, Polaris Partners, and BVF Partners as repeat investors and recent additions including Blood Cancer United's Therapy Acceleration Program.

Name

Crossbow Therapeutics

Legal name

Crossbow Therapeutics, Inc.

Website

https://crossbowtx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Crossbow Therapeutics is a clinical-stage Cambridge, MA biotech developing T-Bolt™ TCR-mimetic antibody T-cell engagers that target intracellular cancer antigens via peptide-HLA complexes, with lead programs CBX-250 (Phase 1 in AML/MDS) and CBX-663 (pre-IND, TERT-targeted) and revenue expected from future pharmaceutical licensing.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• T-cell engager therapies
• TCR-mimetic antibodies
• Cancer immunotherapy
• Bispecific antibodies
• Targeted oncology therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing and Co-development: Pre-commercial biotech company generating revenue through licensing agreements, co-development partnerships, and milestone payments with pharmaceutical companies. Revenue will be generated from drug development milestones, regulatory approvals, and potential future product sales upon FDA approval.
2. Strategic Collaborations: Revenue generated through strategic collaborations with academic institutions and pharmaceutical partners such as MD Anderson Cancer Center, where Crossbow licenses technologies and co-develops therapeutic candidates.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Crossbow Therapeutics develops TCR-mimetic antibody T-cell engager (TCE) immunotherapies for cancer using its proprietary T-Bolt™ platform. The platform engineers bispecific antibodies that recognize intracellular cancer antigens displayed as peptide-HLA complexes on tumor cell surfaces, expanding the target universe beyond what conventional antibodies and existing TCEs can reach. Lead clinical-stage candidates include CBX-250 (cathepsin G-targeting TCE) and CBX-663 (TERT-targeting TCE), with multiple additional pipeline programs.

Product overview

Crossbow Therapeutics is developing T-Bolt™, a proprietary TCR-mimetic antibody technology platform that enables the development of T-cell engager (TCE) immunotherapies targeting intracellular cancer proteins. The company's lead product is CBX-250, a first-in-class TCE targeting Cathepsin G pHLA currently in Phase 1 trials for myeloid malignancies. CBX-663, a second TCE targeting TERT pHLA for solid and hematologic tumors, is advancing toward IND filing. Additional pipeline programs include CBX-589 (Cathepsin G target) and CBX-880 (undisclosed solid tumor target).

Differentiator

Problem solved

Functional benefit

Brands

• T-Bolt™: Proprietary TCR-mimetic antibody technology platform enabling targeting of intracellular cancer antigens for development of T-cell engager therapies.
• CROSSCHECK-001

Products and services

• CBX-250 First-in-class bispecific T-cell engager (TCE) targeting the cathepsin G (CTSG) peptide-HLA (pHLA) complex (HLA-A*02:01-restricted), abundantly expressed on leukemic cells but not on normal myeloid cells. In development for relapsed or refractory myeloid malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS), chronic myelomonocytic leukemia (CMML), and chronic myeloid leukemia (CML). Currently in Phase 1 clinical trial (CROSSCHECK-001, NCT06994676).
• CBX-663 Bispecific T-cell engager targeting the telomerase reverse transcriptase (TERT) peptide-HLA complex (HLA-A*02:01-restricted TERT540 peptide). Contains two binding domains for TERT to enhance tumor cell engagement and immune activation. In development for multiple hematologic and solid tumors including squamous non-small cell lung cancer (sqNSCLC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer, esophageal cancer, and others. TERT is expressed in up to 95% of cancers. IND filing projected for Q3 2026.
• CBX-589 Pipeline program also targeting the Cathepsin G peptide-HLA complex, in discovery/early development stage.
• CBX-880 Pipeline program with undisclosed target for solid tumor and hematologic malignancies, in discovery stage.

Quantifiable outcome

• CBX-250 demonstrated high tumor antigen selectivity and potent antileukemic activity in preclinical in vivo models
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• The University of Texas MD Anderson Cancer CenterflagshipStrategic or Co-development PartnerStrategic collaboration for discovery and preclinical development of CBX-250. Gheath Alatrash, DO, PhD, and Jeffrey Molldrem, MD, led discovery and validation of the CTSG-derived peptide (CG1) via functional studies and mass spectrometry. MD Anderson's ORBIT platform within Therapeutics Discovery division developed the TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for development. Crossbow designed and is conducting the CROSSCHECK-001 clinical study.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Harpoon Therapeutics: Harpoon developed T-cell engagers (TriTAC platform) for oncology and was acquired by Merck in 2024. It serves as a direct historical peer for bispecific T-cell engager biotechs of similar stage and approach to Crossbow.
• Immunocore: Immunocore is a commercial-stage biotech developing TCR-based immunotherapies for cancer and infectious disease, including the approved TCR therapeutic tebentafusp. It is the most directly comparable peer to Crossbow as both companies engineer TCR-based or TCR-mimetic molecules targeting peptide-HLA complexes for oncology.
• Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies for solid tumors, including the approved afami-cel. It is a direct peer in the TCR-based oncology space and competes for similar target classes and HLA-restricted indications as Crossbow's TCR-mimetic programs.
• Immatics: Immatics develops TCR-based immunotherapies and TCR-mimetic antibody products (e.g., ACTengine and TCER formats) targeting intracellular cancer antigens presented on HLA. Its bispecific TCER pipeline most closely mirrors Crossbow's T-Bolt™ T-cell engager approach.
• Maverick Therapeutics: Maverick developed conditionally active T-cell engagers (COBRA platform) for solid tumors and was acquired by Takeda. It is a direct peer to Crossbow in next-generation bispecific T-cell engager development for oncology.

Broad incumbents

• Macrogenics: Macrogenics develops bispecific antibodies and DART-platform T-cell engagers for oncology (e.g., vobramitamab duocarmazine). It is a broader incumbent operating in the same T-cell engager / bispecific antibody category as Crossbow.
• Amgen: Amgen commercializes Blincyto (blinatumomab), the leading BiTE-format bispecific T-cell engager, and operates broadly in oncology biologics. It is a broad incumbent setting the commercial and clinical benchmark against which Crossbow's T-cell engager programs will be evaluated.
• Genmab: Genmab is a leading bispecific antibody platform company behind the approved Epkinly (epcoritamab) and multiple DuoBody-based oncology programs. It is a broad incumbent in the bispecific antibody space that Crossbow competes within for partnerships and pipeline priority.
• Regeneron: Regeneron has a deep bispecific antibody pipeline (e.g., linvoseltamab, odronextamab) and is a broad incumbent in antibody-based oncology therapeutics. It is comparable to Crossbow as a competitor and potential partner/strategic acquirer in the bispecific antibody space.

Emerging players

• Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing targeted oncology therapeutics including T-cell engager and immune-engager programs. It is an emerging player with overlapping modality focus to Crossbow's TCE pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crossbow-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crossbow Therapeutics